Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design

  • Integrating ADC MoA, target biology, payload dynamics, ADC/ICI disposition, and tumor–immune interactions with key clinical biomarkers
  • Iteratively tuning QSP model with preclinical and clinical data to predict PK, efficacy and safety
  • Simulating heterogeneous virtual populations to evaluate dosing strategies and therapeutic performance across ADC monotherapy and combination